TIDMAGL

RNS Number : 0019T

Angle PLC

09 October 2017

 
 For immediate release    9 October 2017

ANGLE plc ("the Company")

CIRCULATING TUMOUR CELLS, HARVESTED FROM BLOOD, GROWN IN THE LABORATORY FOR THE FIRST TIME

Heinrich Heine University researchers demonstrate that CTCs harvested with Parsortix(TM) from leukapheresis blood product can be cultured

Cultured cells continue to proliferate several months after Parsortix(TM) harvest

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that one of its customers has successfully grown circulating tumor cells (CTCs) harvested by Parsortix(TM) in the laboratory. This is the first time the ability to culture CTCs harvested from blood using Parsortix(TM) has been published. The CTCs were isolated from diagnostic leukapheresis (DLA) blood product.

The cells grown in culture harbour genomic abnormalities that confirm their malignant origin. Most of the aberrations were identical to those detected in the uncultured CTCs from the same patient. The cultured cells continue to proliferate several months after Parsortix(TM) harvest, providing a renewable population of cells for ongoing research and investigation outside the patient.

The customer, a research group from the Heinrich Heine University, Düsseldorf, Germany, presented their results at Europe's leading circulating tumour cell (CTC) conference, the Third International Advances in Circulating Tumour Cells (ACTC) Symposium (Rhodes, Greece, 4 to 7 October 2017).

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"This is the first time that a patient's CTCs harvested by Parsortix(TM) have been successfully cultured. The Parsortix(TM) system's capability to harvest living, viable cancer cells is a key differentiator and we believe this will lead to new avenues of research using Parsortix(TM) ."

Dr Hans Neubauer, University Hospital and Medical Faculty of the Heinrich-Riche University of Duesseldorf commented:

"The use of diagnostic leukapheresis blood product provides larger numbers of CTCs than a normal blood sample. The Parsortix(TM) system provides an easy solution for harvesting these CTCs keeping the cells alive and undamaged. The workflow we have developed to culture these cells will allow an intensification of research into new diagnostic and therapeutic solutions."

For further information ANGLE:

 
 ANGLE plc                                 +44 (0) 1483 343434 
 Andrew Newland, Chief Executive 
  Ian Griffiths, Finance Director 
 finnCap Ltd (NOMAD and Joint 
  Broker) 
  Corporate Finance - Adrian 
  Hargrave, Simon Hicks, Kate 
  Bannatyne 
  Corporate Broking - Alice Lane, 
  Nikita Jain                              +44 (0)20 7220 0500 
 WG Partners (Joint Broker) 
  Nigel Barnes                               +44 (0) 203 705 9318 
  Nigel Birks                                +44 (0) 203 705 9316 
 FTI Consulting 
  Simon Conway, Mo Noonan, Stephanie 
  Cuthbert                                   +44 (0) 203 727 1000 
  Kimberly Ha (US)                           +1 212 850 5612

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

This announcement contains inside information.

Notes for editors

   About ANGLE plc     www.angleplc.com

ANGLE is a world-leading liquid biopsy company commercialising a disruptive platform technology that can capture cells circulating in blood, such as cancer cells, even when they are as rare in number as one cell in one billion blood cells, and harvest the cells for analysis.

ANGLE's cell separation technology is called the Parsortix(TM) system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix(TM) is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. Parsortix(TM) has a CE Mark for Europe and FDA authorisation is in process for the United States.

ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/

The analysis of the cells that can be harvested from patient blood with ANGLE's Parsortix(TM) system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.

The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix(TM) system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug's effectiveness.

As well as cancer, the Parsortix(TM) technology has the potential for deployment with several other important cell types in the future.

ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESUGGPPUUPMPUR

(END) Dow Jones Newswires

October 09, 2017 02:02 ET (06:02 GMT)

Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Angle Charts.
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Angle Charts.